Lucentia
Entrepreneur First '25Paris, FR · Founded 2025 · 1 known investors
Lucentia develops AI software that analyses standard cardiac CT scans to extract additional information about the coronary arteries. The approach is designed to detect signs of heart disease earlier without requiring contrast agents or further scans, using imaging that clinicians already perform routinely.
Also known as Lucentia Health
Founders & leadership
Lucentia was founded in 2025 by Sahar Jalal.
Investors · 1
Company profile
researched Aug 2026Lucentia is an early-stage healthcare and digital health company developing artificial intelligence software that converts routine, non-contrast CT scans into detailed coronary diagnostics. The stated aim is to make advanced cardiac imaging faster, more accessible and available earlier in the care pathway, allowing coronary disease risk to be assessed without contrast injection or invasive procedures.
The company was founded in 2025 and is a portfolio company of Entrepreneurs First, which is described as having backed it from inception. Public listings place it at seed stage with a team of 1-10 employees. Company materials frame the ambition as creating a "mammogram of the heart" — a widely deployable screening-style cardiac assessment built on imaging that health systems already perform.
Founding story
Founded in 2025 by Sahar Jalal, whose background spans aerospace engineering and cardiac imaging research at Weill Cornell Medicine, where datasets linking CT scans to coronary anatomy were developed.
Business model
Lucentia develops AI software intended for use by healthcare providers on imaging they already acquire; sources do not describe pricing, contracting or distribution arrangements.
Traction
Sources report only stage and size indicators: founded 2025, seed stage, 1-10 employees, and backing by Entrepreneurs First. No customers, revenue or clinical results are disclosed.
Latest developments
The company emerged from stealth, publicised via an Entrepreneurs First LinkedIn post and reported by TipRanks, with the stated goal of improving the diagnostic power of routine CT scans to detect coronary disease risk earlier.
▸Full profile — market position, technology, go-to-market, geography, risks & controversies
Market position
Positioned in non-invasive cardiac imaging and cardiovascular screening as an early-stage, seed-stage entrant; sources note that clinical validation and reimbursement would be prerequisites for expanding the addressable market and driving provider adoption.
Sources cite the founder's engineering background spanning aerospace and cardiac imaging research at Weill Cornell Medicine, and access to rare datasets linking CT scans to actual coronary anatomy, as a potential source of differentiation in non-invasive coronary diagnostics. The approach avoids contrast agents and additional or invasive imaging.
Technology
AI software that analyses routine non-contrast CT scans to derive detailed coronary diagnostic information, enabling coronary assessment without contrast injections or invasive procedures. Its technical foundation is linked to cardiac imaging research at Weill Cornell Medicine, where rare datasets pairing CT scans with actual coronary anatomy were developed.
Go-to-market
Healthcare providers performing routine CT imaging and conducting cardiovascular risk assessment.
Geography
One public listing records the company's location as New York, NY, United States.
Risks & controversies
Coverage notes that market expansion depends on the technology being clinically validated and reimbursed; no clinical or regulatory milestones are documented in the sources. Several similarly named entities exist online (including unrelated naturopathic and supplement businesses) that should not be confused with this company.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsA LinkedIn post from Entrepreneurs First, reported by TipRanks, announced that portfolio company Lucentia was emerging from stealth with a focus on next-generation heart imaging aimed at detecting coronary disease risk earlier from routine CT scans. EF is described as backing the company 'from day zero'.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- Lucentialucentia.health · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Lucentia do?
- Lucentia builds AI that turns routine non-contrast CT scans into detailed coronary diagnostics for earlier heart disease detection.
- Who founded Lucentia?
- Lucentia was founded by Sahar Jalal in 2025.
- Who are Lucentia's investors?
- Lucentia's investors include Entrepreneur First.
- Where is Lucentia headquartered?
- Lucentia is headquartered in Paris, FR.